EcoDrugPlus

Adrenoceptor Beta 3

Ensembl ID : ENSPPRG00000008424
Gene Symbol: ADRB3
1 Cross references
215 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSPPRG00000002538
Gene Symbol: AGER
4 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSPPRG00000016319
Gene Symbol: ADH5
4 Cross references
401 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSPPRG00000023456
Gene Symbol: AKR1B1
4 Cross references
427 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSPPRG00000019515
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Alpha-Amylase 2b

Ensembl ID : ENSPPRG00000016963
Gene Symbol: LOC109271948
3 Cross references
213 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSPPRG00000011726
Gene Symbol: AOC1
4 Cross references
230 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSPPRG00000003869
Gene Symbol: APP
4 Cross references
276 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSPPRG00000010208
Gene Symbol: AR
3 Cross references
277 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSPPRG00000010880
Gene Symbol: ACE
4 Cross references
93 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSPPRG00000014998
Gene Symbol: AGTR1
3 Cross references
207 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSPPRG00000011465
Gene Symbol: AGTR2
4 Cross references
191 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).